Medicover Genetics NeoThetis Pan-Cancer Plus Panel
Cyprus-based Medicover Genetics has launched the NeoThetis Pan-Cancer Plus Panel, an expansion of its Liquid Biopsy Therapy Selection Portfolio. The new panel analyzes more than 200 genes as well as genomic immunotherapy biomarkers, such as microsatellite instability and blood tumor mutational burden, that are connected to US Food and Drug Administration/European Medicines Agency-approved therapies and adhere to professional society and clinical trial criteria, the company said. NeoThetis Pan-Cancer Plus provides over 1 Mb of genomic coverage and targets more than 2,000 genetic loci using a simple blood draw. Medicover can provide the test in more than 40 countries primarily in Europe, the Middle East and North Africa, South Africa, Asia, and South America, a company spokesperson said.